FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to endothelin receptor antibody (ETA) and TGF-β fusion proteins Trap, and can be used in medicine in the treatment of pulmonary arterial hypertension, pulmonary fibrosis or cardiovascular fibrosis. Disclosed is a fusion protein containing an antibody to ETA and TGF-β Trap or a fragment thereof, which are able to block the function of TGF-β. Said TGF-β Trap consists of the extracellular end of the TGF-β receptor 2 types and said ETA antibody is characterized by the presence of three CDRs in the light chain with SEQ ID NO: 8, 32 and 50 or 205 and three CDRs in the heavy chain with SEQ ID NO: 70, 92 and 116.
EFFECT: invention provides the production of a fused protein with a dual mechanism of action: on the one hand, it can block the signaling pathway of ETAR and reduce the resistance of blood vessels to pulmonary blood flow, on the other hand, it can block the signaling pathway of TGF-β and relieve fibrosis and remodeling of pulmonary arterioles.
30 cl, 4 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTIBODY AGAINST HUMAN INTERLEUKIN-4 ALPHA RECEPTOR, METHOD OF ITS PREPARATION AND ITS APPLICATION | 2021 |
|
RU2807060C1 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| ANTIGEN-BINDING POLYPEPTIDE BINDING TO CD47, AND USE THEREOF | 2021 |
|
RU2833294C2 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2019 |
|
RU2781542C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
